The antibiotic era: Reform, resistance, and the pursuit of a rational therapeutics

The Antibiotic Era: Reform, Resistance, and The Pursuit of a Rational Therapeutics

Volumn , Issue , 2014, Pages 1-309

  Podolsky, Scott H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84951270417     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (286)

1. Sharon Begley and Martha Brant, “The End of Antibiotics?” Newsweek (Mar. 7, 1994): 63.
2. Sharon Begley, Martha Brant, Pat Wingert, and Mary Hager, “The End of Antibiotics,” Newsweek (Mar. 28, 1994): 47–51.
3. Geoffrey Cowley, John F. Lauerman, Karen Springen, Mary Hager, and Pat Wingert, “Too Much of a Good Thing” [internal story capsule], Newsweek (Mar. 28, 1994): 50–51.
4. Robert Bud, Penicillin: Triumph and Tragedy(New York: Oxford University Press, 2007).
5. Jeremy A. Greene, “What’s in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine,” Journal of the History of Medicine and Allied Sciences 66 (2011): 425–67.
6. John C. Burnham, “Medicine’s Golden Age: What Happened to It?” Science 215 (1982): 1474–79.
7. Allan M. Brandt and Martha Gardner, “The Golden Age of Medicine?” in Roger Cooter and John Pickstone, eds., Medicine in the Twentieth Century(Amsterdam: Harwood Academic Publishers, 2000), 21–37.
8. Harry F. Dowling, Fighting Infection: Conquests of the Twentieth Century(Cambridge, MA: Harvard University Press, 1977).
9. Wesley W. Spink, Infectious Diseases: Prevention and Treatment in the Nineteenth and Twentieth Centuries (Minneapolis: University of Minnesota Press, 1978).
10. David Greenwood, Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph(New York: Oxford University Press, 2008).
11. Gladys L. Hobby, Penicillin: Meeting the Challenge (New Haven: Yale University Press, 1985).
12. John E. Lesch, The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine (New York: Oxford University Press, 2007).
13. Thomas Maeder, Adverse Reactions(New York: William Morrow, 1994).
14. James Whorton, “ ‘Antibiotic Abandon’: The Resurgence of Therapeutic Rationalism,” in John Parascandola, ed., The History of Antibiotics: A Symposium(Madison, WI: American Institute of the History of Pharmacy, 1980), 125–36.
15. Harry M. Marks, “Cortisone: A Year in the Political Life of a Drug,” Bulletin of the History of Medicine 66 (1992): 419–39.
16. David Cantor, “Cortisone and the Politics of Drama, 1949–1955,” in John V. Pickstone, ed., Medical Innovations in Historical Perspective(Basingstoke, UK: Macmillan, 1992), 165–84.
17. Leo B. Slater, “Industry and Academy: The Synthesis of Steroids,” Historical Studies in the Physical and Biological Sciences 30 (2000): 443–80.
18. Micky Smith, A Social History of the Minor Tranquilizers: The Quest for Small Comfort in the Age of Anxiety(New York: Pharmaceutical Products, 1991).
19. Susan L. Speaker, “From ‘Happiness Pills’ to ‘National Nightmare’: Changing Cultural Assessment of Minor Tranquilizers in America, 1955–1980,” Journal of the History of Medicine and Allied Sciences 52 (1997): 338–76.
20. David Healy, The Antidepressant Era(Cambridge, MA: Harvard University Press, 1997).
21. Nicolas Rasmussen, On Speed: The Many Lives of Amphetamine(New York: New York University Press, 2008).
22. David Herzberg, Happy Pills: From Miltown to Prozac(Baltimore: Johns Hopkins University Press, 2009).
23. David Healy, The Creation of Psychopharmacology(Cambridge, MA: Harvard University Press, 2002).
24. Jeremy A. Greene, Prescribing by Numbers: Drugs and the Definition of Disease (Baltimore: Johns Hopkins University Press, 2007).
25. Jeremy A. Greene and Scott H. Podolsky, “Reform, Regulation, and Pharmaceuticals—The Kefauver-Harris Amendments at 50,” New England Journal of Medicine 367 (2012): 1481–83.
26. Daniel Carpenter: Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA(Princeton: Princeton University Press, 2010), 118–227.
27. Scott H. Podolsky and Jeremy A. Greene, “Combination Drugs: Hype, Harm, and Hope,” New England Journal of Medicine 365 (2011): 488–91.
28. John Krige, American Hegemony and the Postwar Reconstruction of Science in Europe(Cambridge, MA: MIT Press, 2006).
29. Ronald A. Arky, Charles S. Davidson, Edward H. Kass, and Jerome O. Klein, “Faculty of Medicine—Memorial Minute,” Harvard Gazette (Sept. 8, 1989): 9–10.
30. Brad Spellberg, Rising Plague: The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them (New York: Prometheus Books, 2009), 78, 195–98, 206.
31. Tanya Stivers, Prescribing under Pressure: Parent-Physician Conversations and Antibiotics(New York: Oxford University Press, 2007).
32. Dominique A. Tobbell, Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences (Berkeley: University of California Press, 2012).
33. G. E. R. Lloyd, Magic, Reason, and Experience: Studies in the Origin and Development of Greek Science(Cambridge: Cambridge University Press, 1979), 10–58.
34. James Longrigg, Greek Rational Medicine: Philosophy and Medicine from Alcmaeon to the Alexandrians(New York: Routledge, 1993).
35. John Harley Warner, The Therapeutic Perspective: Medical Practice, Knowledge, and Identity in America, 1820–1885(Cambridge, MA: Harvard University Press, 1986), 37–57.
36. Ernest Jawetz, “Patient, Doctor, Drug, and Bug,” Antibiotics Annual (1957-1958): 295.
37. W. Clarke Wescoe, “Lewis Carroll Might Have Written It,” Food Drug Cosmetic Law Journal26 (1971): 463.
38. Ernest Jawetz, “Patient, Doctor, Drug, and Bug,” Antibiotics Annual (1957-1958): 295.
39. S. L. Montgomery, “Codes and Combat in Medical Discouse,” Science as Culture2 (1991): 341–90.
40. Christoph Gradmann, “Invisible Enemies: Bacteriology and the Language of Politics in Imperial Germany,” Science in Context13 (2000): 9–30.
41. Harry F. Dowling, Fighting Infection: Conquests of the Twentieth Century(Cambridge: Harvard University Press, 1977), 1–54.
42. Peter Keating, “Vaccine Therapy and the Problem of Opsonins,” Journal of the History of Medicine and Allied Sciences43 (1988): 275–96
43. William C. Summers, Félix d’Herelle and the Origins of Molecular Biology (New Haven: Yale University Press, 1999)
44. Scott H. Podolsky, “Cultural Divergence: Elie Metchnikoff’s Bacillus bulgaricus Therapy and His Underlying Conception of Health,” Bulletin of the History of Medicine72 (1998): 1–27
45. Allan M. Brandt, No Magic Bullet: A Social History of Venereal Disease in the United States since 1880 (New York: Oxford University Press 1985).
46. John Parascandola, Sex, Sin, and Science: A History of Syphilis in America(Westport, CT: Praeger, 2008).
47. Leo M. Slater, War and Disease: Biomedical Research on Malaria in the Twentieth Century(New Brunswick, NJ: Rutgers University Press, 2009), 59–83.
48. Sinclair Lewis, Arrowsmith(New York: Harcourt, Brace, 1925).
49. Scott H. Podolsky, Pneumonia before Antibiotics: Therapeutic Evolution and Evaluation in Twentieth-Century America (Baltimore: Johns Hopkins University Press, 2006).
50. John E. Lesch, The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine (New York: Oxford University Press, 2007)
51. Gladys L. Hobby, Penicillin: Meeting the Challenge (New Haven: Yale University Press, 1985)
52. Robert Bud, Penicillin: Triumph and Tragedy(New York: Oxford University Press, 2007)
53. Simon Flexner and James Thomas Flexner, William Henry Welch and the Heroic Age of American Medicine(New York: Viking Press, 1941), 150–80.
54. Victoria A. Harden, Inventing the NIH: Federal Biomedical Research Policy, 1887–1937 (Baltimore: Johns Hopkins University Press, 1986).
55. Evelynn Maxine Hammonds, Childhood’s Deadly Scourge: The Campaign to Control Diphtheria in New York City, 1880–1930(Baltimore: Johns Hopkins University Press, 1999).
56. Martha L. Sternberg, George Miller Sternberg: A Biography (Chicago: American Medical Association, 1920)
57. M. W. Ireland and Joseph F. Siler, Medical Department of the United States Army in the World War, vol. 9: Communicable and Other Diseases(Washington, DC: U.S. Government Printing Office, 1928).
58. William Haynes, American Chemical Industry, vol. 6: The Chemical Companies(New York: Van Nostrand, 1949), 320–24.
59. George Washington Corner, A History of the Rockefeller Institute, 1901–1953: Origins and Growth(New York: Rockefeller Institute Press, 1964).
60. Rosemary Stevens, American Medicine and the Public Interest, rev. ed. (Berkeley: University of California Press, 1998).
61. George Weisz, Divide and Conquer: A Comparative History of Medical Specialization(New York: Oxford University Press, 2006).
62. Joseph B. Kirsner, “One Hundred Years of American Gastroenterology,” in Russell C. Maulitz and Diana E. Long, eds., Grand Rounds: One Hundred Years of Internal Medicine(Philadelphia: University of Pennsylvania Press, 1988), 117–57.
63. Barnett Cohen, Chronicles of the Society of American Bacteriologists, 1899–1950(Baltimore: Society of American Bacteriologists, 1950), 16.
64. Maxwell Finland, “The Serum Treatment of Lobar Pneumonia,” NEJM202 (1930): 1244–47.
65. Harry F. Dowling, Theodore J. Abernathy, and Clarence R.Hartman, “Should Serum Be Used in Addition to Sulfapyridine in the Treatment of Pneumococcic Pneumonia?” JAMA 115 (1940): 2125–28.
66. Marvin Turck, “Harry F. Dowling, M.D., 1904–2000,” Journal of Infectious Diseases185 (2002): 1003–4.
67. Edward H. Kass, “History of the Subspecialty of Infectious Diseases in the United States,” in Maulitz and Long, Grand Rounds, 87–115.
68. Theodore E. Woodward, ed., The Armed Forces Epidemiological Board: The Histories of Its Commissions(Washington, DC: Office of the Surgeon General, 1994).
69. James Harvey Young, “The ‘Elixir Sulfanilamide’ Disaster,”Emory University Quarterly14 (1958): 230–37.
70. Daniel Carpenter, Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA(Princeton: Princeton University Press, 2010), 85–112.
71. Arthur A. Daemmrich, Pharmacopolitics: Drug Regulation in the United States and Germany(Chapel Hill: University of North Carolina Press, 2004), 54–58.
72. Harry Gold, “Clinical Pharmacology—A Historical Note,” Journal of Clinical Pharmacology and the Journal of New Drugs7 (1967): 309–11
73. Dominique A. Tobbell, Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences (Berkeley: University of California Press, 2012), 54–57.
74. Peter Temin, “Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry,” Bell Journal of Economics10 (1979): 429–46.
75. Walsh McDermott, “Pharmaceuticals: Their Role in Developing Societies,” Science209 (1980): 243.
76. Clifford W. Price, William A. Randall, and Henry Welch, “Bacteriological Studies of Aureomycin,” Annals of the New York Academy of Sciences 51 (1948): 211–17.
77. Henry Welch, “Certification of Antibiotics,” Public Health Reports71 (1956): 594–99.
78. Louis T. Wright, James C. Whitaker, Robert S. Wilkinson, and Malcolm S. Beinfield, “The Treatment of Lymphogranuloma Venereum with Terramycin,” Antibiotics and Chemotherapy 1 (1951): 193–97.
79. Harry F. Dowling, Mark H. Lepper, Lewis K. Sweet, and Robert L. Brickhouse, “Studies on Serum Concentrations in Humans and Preliminary Observations on the Treatment of Human Infections with Aureomycin,” Annals of the New York Academy of Sciences 51 (1948): 241–45.
80. Maxwell Finland, Harvey Shields Collins, and Tom Fite Paine., “Aueromycin: A New Antibiotic,” JAMA138 (1948): 946–49.
81. Jasper H. Kane, A. C. Finley, and B. A. Sobin, “Antimicrobial Agents from Natural Sources,” Annals of the New York Academy of Sciences53 (1950): 226–28.
82. John Gunther, “Inside Pfizer” [advertising supplement, New York Times(Mar. 23, 1958).
83. Arthur Daemmrich, “Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era,” History and Technology 25 (2009): 243–47.
84. Louis Lasagna, The Doctors’ Dilemmas(New York: Harper & Brothers, 1962), 134–36.
85. Barry Meier, Pain Killer: A Wonder Drug’s Trail of Addiction and Death(New York: Rodale, 2003), 193–222.
86. Scott H. Podolsky, “Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America,” Bulletin of the History of Medicine 83 (2009): 352–55.
87. F. A. Hochstein et al., “Terramycin. VII. The Structure of Terramycin,” Journal of the American Chemical Society74 (1952): 3708–9.
88. F. A. Hochstein et al., “The Structure of Terramycin,” Journal of the American Chemical Society75 (1953): 5455–75.
89. Henry Welch, “Erythromycin—A New Broad Spectrum Antibiotic,” Antibiotics and Chemotherapy2 (1952): 279–80.
90. David Greenwood, Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph(New York: Oxford University Press, 2008), 236–37.
91. George Urdang, “The Antibiotics and Pharmacy,” Journal of the History of Medicine6 (1951): 404.
92. Lizabeth Cohen, A Consumers’ Republic: The Politics of Mass Consumption in Postwar America(New York: Knopf, 2003), 292–344.
93. John E. McKeen, “The Antibiotic Vista,” Drug and Cosmetic Industry 66 (1950): 652.
94. Charles O. Jackson, Food and Drug Legislation in the New Deal (Princeton: Princeton University Press, 1970).
95. Eric W. Boyle, Quack Medicine: A History of Combating Health Fraud in Twentieth-Century America (Santa Barbara, CA: Praeger, 2013), 17–38.
96. Austin Smith, “The Council on Pharmacy and Chemistry,” in Morris Fishbein, A History of the American Medical Association, 1847–1947(Philadelphia: Saunders, 1947), 883.
97. Jennie Gregory, “An Evaluation of Medical Periodicals,” Bulletin of the Medical Library Association25 (1937): 172–88.
98. Harry F. Dowling, Medicines for Man: The Development, Regulation, and Use of Prescription Drugs(New York: Knopf, 1970), 172.
99. Iago Galdston, ed., The Impact of the Antibiotics on Medicine and Society(New York: International Universities Press, 1958).
100. Caroline A. Chandler, “Antibiotic Therapy,” Yale Journal of Biology and Medicine 25 (1953): 369.
101. Ernest Jawetz, “Infectious Diseases: Problems of Antimicrobial Therapy,” Annual Review of Medicine5 (1954): 1–2.
102. Maxwell Finland and Louis Weinstein, “Complications Induced by Antimicrobial Agents,” NEJM248 (1953): 220–26.
103. W. H. Oatway, “Delays in the Diagnosis of Tuberculosis from the Incautious Use of Antibiotics,” Arizona Medicine8 (1951): 25–28.
104. James W. Haviland, “Advances in Antibiotic Therapy,” Annals of Internal Medicine 39 (1953): 313–15.
105. D aniel Carpenter, Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA(Princeton: Princeton University Press, 2010), 118–227.
106. J. Ungar, “Synergistic Effect of Para-aminobenzoic Acid and Sulphapyridine on Penicillin,” Nature152 (1943): 245–46.
107. Joseph W. Bigger, “Synergic Action of Penicillin and Sulphonamides,” Lancet 2 (1944): 142–45.
108. C. H. Browning and R. Gulbranson, “An Interference Phenomenon in the Action of Chemotherapeutic Substances in Experimental Trypanosome Infections,” Journal of Pathology and Bacteriology 25 (1922): 395–97.
109. Tobias Bollanbach and Roy Kishony, “Resolution of Gene Regulatory Conflicts Caused by Combinations of Antibiotics,” Molecular Cell42 (2011): 413–25.
110. E. Jawetz, J. B. Gunnison, J. B. Bruff, and V. R. Coleman, “Studies on Antibiotic Synergism and Antagonism: Synergism among Seven Antibiotics against Various Bacteria In Vitro,” Journal of Bacteriology64 (1952): 30–31.
111. Ernest Jawetz, “Antibiotic Synergism and Antagonism: Review of Experimental Evidence,” Archives of Internal Medicine90 (1952): 308.
112. Hobart A. Reimann, “Infectious Diseases: Sixteenth Annual Review of Significant Publications,” Archives of Internal Medicine 87 (1951): 128.
113. Henry Welch, The Manual of Antibiotics, 1954–1955 (New York: Medical Encyclopedia, 1954), 33, 55–57.
114. Charles S. Davidson, “Antibiotics Plus?” American Journal of Clinical Nutrition 4 (1956): 687–88.
115. R. C. Anderson, H. M. Worth, P. N. Harris, and K. K. Chen, “Vancomycin, A New Antibiotic: IV. Pharmacologic and Toxicologic Studies,” Antibiotics Annual (1956-1957): 75–81.
116. Kevin Outterson, “The Legal Ecology of Resistance: The Role of Antibiotic Resistance in Pharmaceutical Innovation,” Cardoza Law Review31, no. 3 (2010): 613–78.
117. Henry Welch, “A Rational Approach to Combined Antibiotic Therapy,” Antibiotic Medicine and Clinical Therapy3 (1956): 377.
118. Harry F. Dowling, “A New Generation,” Antibiotic Medicine and Clinical Therapy 3 (1956): 25–26.
119. Lizabeth Cohen, A Consumer’s Republic: The Politics of Mass Consumption in Postwar America(New York: Knopf, 2003).
120. Maxwell Finland, “The New Antibiotic Era: For Better or for Worse?” Antibiotic Medicine and Clinical Therapy4 (1957): 18.
121. Roy Porter, Health for Sale: Quackery in England, 1660–1850(New York: Manchester University Press, 1989), 21–59.
122. William Osler, The Principles and Practice of Medicine: Designed for the Use of Practitioners and Students of Medicine(New York: D. Appleton, 1892).
123. Charles S. Bryan, “ ‘The Greatest Brahmin’: Overview of a Life,” in Scott H. Podolsky and Charles S. Bryan, eds., Oliver Wendell Holmes: Physician and Man of Letters(Sagamore Beach, MA: Science History Publications, 2009), 3–21.
124. James C. Whorton, “ ‘Antibiotic Abandon’: The Resurgence of Therapeutic Rationalism,” in John Parascandola, ed., The History of Antibiotics: A Symposium(Madison: American Institute of the History of Pharmacy, 1980), 125–36.
125. Henry P. Loomis, “Physicians and Proprietary Remedies,” JAMA 45 (1905): 1782.
126. James G. Burrow, AMA: Voice of American Medicine (Baltimore: Johns Hopkins Press, 1963), 74–75, 107–31.
127. James Harvey Young, The Medical Messiahs: A Social History of Health Quackery in Twentieth-Century America(Princeton: Princeton University Press, 1967), 129–32.
128. Harold S. Diehl, “Medicinal Treatment of the Common Cold,” JAMA 101 (1933): 2047.
129. W. D. Sutliff, “Adequate Tests of Curative Therapy in Man,” Annals of Internal Medicine10 (1936): 90.
130. Harry M. Marks, “Trust and Mistrust in the Marketplace: Statistics and Clinical Research, 1945–1960,” History of Science 38 (2000): 344.
131. Iain Chalmers, Estela Dukan, Scott H. Podolsky, and George Davey Smith, “The Advent of Fair Treatment Allocation Schedules in Clinical Trials during the 19th and Early 20th Centuries,” Journal of the Royal Society of Medicine 105 (2012): 221–27.
132. Maxwell Finland, “The Serum Treatment of Lobar Pneumonia,” NEJM202 (1930): 1244–47.
133. Maxwell Finland, “Controlling Clinical Therapeutic Experiments with Specific Serums: With Particular Reference to Antipneumococcus Serums,” NEJM225 (1941): 495–506.
134. Monroe D. Eaton, “Chemotherapy of Virus and Rickettsial Infections,” Annual Review of Microbiology 4 (1950): 223–46.
135. Joseph E. Smadel, “Present Status of Antibiotic Therapy in Viral and Rickettsial Disease,” Bulletin of the New York Academy of Medicine 27 (1951): 221–31.
136. Gordon Meikeljohn and Robert I. Shragg, “Aureomycin in Primary Atypical Pneumonia: A Controlled Evaluation,” JAMA 140 (1949): 391.
137. Maxwell Finland, “Antimicrobial Treatment for Viral and Related Infections: I. Antibiotic Treatment of Primary Atypical Pneumonia,” NEJM247 (1952): 318.
138. Austin Bradford Hill, “The Clinical Trial,” NEJM 247 (1952): 113–19.
139. Donald Mainland, “The Modern Method of Clinical Trial” Methods in Medical Research6 (1954): 152–59.
140. D ominique A. Tobbell, Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and its Consequences(Berkeley: University of California Press, 2012), 54–57.
141. Louis Lasagna, Frederick Mosteller, John M. von Felsinger, and Henry K. Beecher, “A Study of the Placebo Response,” American Journal of Medicine16 (1954): 770–79.
142. L ouis Lasagna, “The Controlled Clinical Trial: Theory and Practice,” Journal of Chronic Diseases1 (1955): 353.
143. Austin Smith, “The Challenge of New Drugs to the Pharmaceutical Industry,” Antibiotics Annual (1959-1960): 16.
144. Maxwell Finland, “The Challenge of New Drugs to the Clinical Investigator,” Antibiotics Annual (1959-1960): 24.
145. Richard Harris, The Real Voice(New York: Macmillan, 1964).
146. Arthur Maass, Congress and the Common Good(New York: Basic Books, 1983), 212–13.
147. D aniel Carpenter, Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA(Princeton: Princeton University Press, 2010), 118–227.
148. Harry M. Marks, The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990(New York: Cambridge University Press, 1997), 71–97.
149. Robert Bud, “Antibiotics, Big Business, and Consumers: The Context of Government Investigations into the Postwar American Drug Industry,” Technology and Culture46 (2005): 329–49
150. Dominique A. Tobbell, Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences(Berkeley: University of California Press, 2012), 69–76.
151. Federal Trade Commission, Economic Report on Antibiotics Manufacture(Washington, DC: U.S. Government Printing Office, 1958).
152. Abraham Flexner, Medical Education in the United States and Canada(New York: Carnegie Foundation for the Advancement of Teaching, 1910)
153. Kenneth M. Ludmerer, Learning to Heal: The Development of American Medical Education(New York: Basic Books, 1985), 166–9.
154. Thomas Neville Bonner, Iconoclast: Abraham Flexner and a Life in Learning(Baltimore: Johns Hopkins University Press, 2002), 69–90.
155. Ruth Walrad, The Misrepresentation of Arthritis Drugs and Devices in the United States(New York: Arthritis and Rheumatism Foundation, 1960).
156. Eric Boyle: Quack Medicine: A History of Combating Health Fraud in Twentieth-Century America (Santa Barbara, CA: Praeger, 2013), 135.
157. Philip J. Hilts, Protecting America’s Health: The FDA, Business, and One Hundred Years of Regulation(New York: Alfred A. Knopf, 2003), 117–28.
158. Richard H. Thaler and Cass R. Sunstein, Nudge: Improving Decisions about Health, Wealth, and Happiness(New Haven: Yale University Press, 2008).
159. Louis Lasagna, The Doctors’ Dilemmas(New York: Harper & Brothers, 1962), 167–68.
160. Louis Lasagna, “Thalidomide—A New Nonbarbiturate Sleep-Inducing Drug,” Journal of Chronic Diseases11 (1960): 627–31.
161. Ruth R. Faden, Tom L. Beauchamp, and Nancy M. King, A History and Theory of Informed Consent(New York: Oxford University Press, 1986), 202–5.
162. David J. Rothman, Strangers at the Bedside: A History of How Law and Bioethics Transformed Medical Decision Making(New York: Basic Books, 1991), 63–67.
163. J. Dubos, ed., Bacterial and Mycotic Infections of Man, 3rd ed. (Philadelphia: J. B. Lippincott, 1958), 686–87.
164. James Harvey Young, The Medical Messiahs: A Social History of Health Quackery in Twentieth-Century America(Princeton: Princeton University Press, 1967), 131.
165. L eonard Engel, Medicine Makers of Kalamazoo(New York: McGraw Hill, 1961), 212–13.
166. Maxwell Finland, “Combinations of Antimicrobial Drugs: Trimethoprim-Sulfamethoxazole,” NEJM291 (1974): 624–27.
167. Scott H. Podolsky and Jeremy A. Greene, “Combination Drugs: Hype, Harm, and Hope,” NEJM365 (2011): 488–91.
168. W. Clarke Wescoe, “Lewis Carroll Might Have Written It,” Food Drug Cosmetic Law Journal26 (1971): 463.
169. G. E. R. Lloyd, Magic, Reason, and Experience: Studies in the Origin and Development of Greek Science(Cambridge: Cambridge University Press, 1979), 10–58.
170. Michael McVaugh, The Rational Surgery of the Middle Ages (Florence: Sismel, Edizioni del Galluzzo, 2006).
171. Harry M. Marks, The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990(New York: Cambridge University Press, 1997), 17–41.
172. Jeremy A. Greene and Scott H. Podolsky, “Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America,” Bulletin of the History of Medicine 83 (2009): 331–77.
173. James Whorton, “ ‘Antibiotic Abandon’: The Resurgence of Therapeutic Rationalism,” in John Parascandola, ed., The History of Antibiotics: A Symposium(Madison, WI: American Institute of the History of Pharmacy, 1980), 125–36.
174. Richard A. Kern, “Abuse of Sulfonamides in the Treatment of Acute Catarrhal Fever,” United States Naval Medical Bulletin 44 (1945): 686–94.
175. Maurice A. Schnitker, “Some Abuses of the Antibiotic Agents,” Ohio State Medical Journal 43 (1947): 1140.
176. Henry C. Sweany, “The Use and Misuse of Antimicrobials,” Missouri Medicine 53 (1956): 1068.
177. Erwin Neter, “Use and Abuse of Antibiotics,” Virginia Medical Monthly81 (1954): 362.
178. William E. Apperson, “Streptomycin in Tuberculosis: Its Use and Abuse,” Virginia Medical Monthly 77 (1950): 215.
179. Wendell H. Hall, “The Abuse and Misuse of Antibiotics,” Minnesota Monthly 35 (1952): 629.
180. John T. MacFarlane and Michael Worboys, “The Changing Management of Acute Bronchitis in Britain, 1940–1970: The Impact of Antibiotics,” Medical History 52 (2007): 47–72.
181. George R. Fisher, “The Use and Abuse of Antibiotics,” Journal of the Iowa State Medical Society 50 (1960): 245.
182. William A. Nolen and Donald E. Dille, “Use and Abuse of Antibiotics in a Small Community,” NEJM 257 (1957): 33–34.
183. Thomas Maeder, Adverse Reactions(New York: William Morrow, 1994), 343–47.
184. William S. Jordan, “Colds, Drugs, and Doctors,” Antibiotics and Chemotherapy 11 (1961): 372.
185. Paul D. Stolley and Louis Lasagna, “Prescribing Patterns of Physicians,” Journal of Chronic Diseases 22 (1969): 396.
186. Paul D. Stolley et al., “Drug Prescribing and Use in an American Community,” Annals of Internal Medicine76 (1972): 538.
187. Winifred B. Harm, “A Medical Audit Is a Medical Education,” Modern Hospital 85 (Nov. 1955): 96.
188. Don W. Branham, “The Internal Medical Audit,” Journal of the Oklahoma State Medical Association 53 (1960): 805–7.
189. Alan Gittelsohn, “Small Area Variations in Health Care Delivery,” Science182 (1973): 1102–8.
190. Andrew W. Roberts and James A. Visconti, “The Rational and Irrational Use of Systemic Antimicrobial Drugs,” American Journal of Hospital Pharmacy29 (1972): 828–34.
191. Henry E. Simmons and Paul D. Stolley, “This Is Medical Progress? Trends and Consequences of Antibiotic Use in the United States,” JAMA 227 (1974): 1024.
192. Richard A. Gleckman and Morton A. Madoff, “Environmental Pollution with Resistant Microbes,” NEJM281 (1969): 677.
193. Maxwell Finland, “Changing Patterns of Susceptibility of Common Bacterial Pathogens to Antimicrobial Agents,” Annals of Internal Medicine 76 (1972): 1009–36.
194. Elizabeth Siegel Watkins, On the Pill(Baltimore: Johns Hopkins University Press, 1998), 103–28.
195. Marion J. Finkel, “Magnitude of Antibiotic Use,” Annals of Internal Medicine 89 (1978): 791.
196. Dominique A. Tobbell, Pills, Power, and Policy: The Struggle for Drug Reform in Cold War America and Its Consequences(Berkeley: University of California Press, 2012), 147–92.
197. Dominique Tobbell, “Plow, Town, and Gown: The Politics of Family Practice in 1960s America,” Bulletin of the History of Medicine87 (2013): 648–80.
198. W. Clarke Wescoe, “Lewis Carroll Might Have Written It,” Food Drug Cosmetic Law Journal26 (1971): 463.
199. Michael Halberstam, The Pills in Your Life(New York: Grosset & Dunlap, 1972), 67–68.
200. Nea D’Amelio, “What Young Doctors Told Us about Antibiotic Overkill,” Medical Times102 (1974): 148.
201. Robert Bud, Penicillin: Triumph and Tragedy(New York: Oxford University Press, 2007), 116–39.
202. Barry Meier, Pain Killer: A “Wonder” Drug’s Trail of Addiction and Death(Emmaus, PA: Rodale, 2003), 195.
203. Louis Lasagna, “Statistics, Sophistication, Sophistry, and Sacred Cows,” Clinical Research Proceedings3 (1955): 185–87.
204. Dominique A. Tobbell, “Who’s Winning the Human Race? Cold War as Pharmaceutical Political Strategy,” Journal of the History of Medicine and Allied Sciences64 (2009): 429–73.
205. Philip A. Pizzo, K. J. Robichaud, Fred A. Gill, and Frank G. Witebsky, “Empiric Antibiotic and Antifungal Therapy for Cancer Patients with Prolonged Fever and Neutropenia,” American Journal of Medicine 72 (1982): 101–10.
206. James Lee, Dennis Hefner, Allen Dobson, and Ralph Hardy., “Evaluation of the Maximum Allowable Cost Program,” Health Care Financing Review 4 (1983): 71–82.
207. Edward H. Kass, “Antimicrobial Drug Usage in General Hospitals in Pennsylvania,” Annals of Internal Medicine 89 part 2 (1978): 800–801.
208. Stefan Timmermans and Marc Berg, The Gold Standard: The Challenge of Evidence-Based Medicine and Standardization in Health Care(Philadelphia: Temple University Press, 2003).
209. William R. Fifer, “Antibiotic Utilization Audit: Basic Considerations,” Quality Review Bulletin 5 (1979): 9–12.
210. Gerald J. Jogerst and Stephen E. Dippe, “Antibiotic Use among Medical Specialties in a Community Hospital,” JAMA245 (1981): 842–46.
211. David Greenwood, Antimicrobial Drugs: Chronicle of a Twentieth-Century Medical Triumph(New York: Oxford University Press, 2008), 237.
212. John E. McGowan Jr. and Maxwell Finland, “Usage of Antibiotics in a General Hospital: Effect of Requiring Justification,” Journal of Infectious Diseases130 (1974): 165–68.
213. John E. McGowan and Maxwell Finland, “Effects of Monitoring the Usage of Antibiotics: An Interhospital Comparison,” Southern Medical Journal 69 (1976): 193–95.
214. George Gee Jackson, “Antibiotic Policies, Practices and Pressures,” Journal of Antimicrobial Chemotherapy5 (1979): 1–5.
215. C. Henry Kempe, “A Rational Approach to Antibiotic Therapy of Childhood Infections,” Postgraduate Medicine24 (Oct. 1958): 339.
216. Reynold Spector and Allen H. Heller, “Education vs. Restriction in Rational Use of Antibiotics,” Hospital Formulary13 (Apr. 1978): 273.
217. William Schaffner, Wayne A. Ray, and Charles F. Federspiel, “Surveillance of Antibiotic Prescribing in Office Practice,” Annals of Internal Medicine 89 part 2 (1978): 796–99.
218. William Schaffner, Wayne A. Ray, Charles F. Federspiel, and William O. Miller, “Improving Antibiotic Prescribing in Office Practice: A Controlled Trial of Three Educational Methods,” JAMA250 (1983): 1728–32.
219. Stephen R. Jones et al., “The Effect of an Educational Program upon Hospital Antibiotic Use,” American Journal of the Medical Sciences273 (1977): 79–85.
220. James W. Smith and Stephen R. Jones, “An Educational Program for the Rational Use of Antimicrobial Agents,” Southern Medical Journal70 (1977): 215–18.
221. Charles V. Sanders, “Memorial: Jay P. Sanford, 1928–1996,” Transactions of the American Clinical and Climatological Society 112 (2001): 44–46.
222. Leighton E. Cluff, “The Prescribing Habits of Physicians,” Hospital Practice 2 (Sept. 1967): 103.
223. Allen E. Hussar, “A Proposed Crusade for the Rational Use of Antibiotics,” Antibiotics Annual (1954-1955): 381.
224. Martin Wood, “The Politicization of Antimicrobial Resistance,” Current Opinion in Infectious Diseases11 (1998): 649–51.
225. John W. Kingdon, Agendas, Alternatives, and Public Policies, 2nd ed. (New York: Longman, 2003).
226. Carsten Timmermann and Julie Anderson, Devices and Designs: Medical Technologies in Historical Perspective(New York: Palgrave MacMillan, 2006), 195–211.
227. Lawrence Besserman, “The Challenge of Periodization: Old Paradigms and New Perspectives,” in The Challenge of Periodization: Old Paradigms and New Perspectives(New York: Garland, 1997), 3–27.
228. Allan M. Brandt, No Magic Bullet: A Social History of Venereal Disease in the United States since 1980 (New York: Oxford University Press, 1985).
229. Hobart A. Reimann, “The Misuse of Antimicrobics,” Medical Clinics of North America 45 (1961): 855.
230. McDermott, “Host Factors in Experimental Staphylococcal Infection: The Problem of Staphylococcal Infections,” Annals of the New York Academy of Sciences 65 (1956): 58–66.
231. Walsh McDermott, “Microbial Persistance,” Yale Journal of Biology and Medicine30 (1958): 257–91.
232. N. H. Creager, “Adaptation or Selection? Old Issues and New Stakes in the Postwar Debates over Bacterial Drug Resistance,” Studies in the History and Philosophy of Biology and Biomedical Science38 (2007): 159–90.
233. Perrin H. Long, “The Use and Abuse of Chemotherapeutic and Antibiotic Agents,” NEJM 237 (1947): 837–39.
234. Maxwell Finland, “Antibacterial Agents: Uses and Abuses in Treatment and Prophylaxis,” Rhode Island Medical Journal43 (1960): 503.
235. Tsutomu Watanabe, “Infective Heredity of Multiple Drug Resistance in Bacteria,” Bacteriological Reviews27 (1963): 87–115.
236. Leighton E. Cluff, “Infectious Diseases: A Perspective,” Journal of Infectious Diseases 129 (1974): 88.
237. Calvin M. Kunin, “Antibiotic Accountability,” NEJM 301 (1979): 380.
238. Dennis G. Maki, “A Study of Antimicrobial Misuse in a University Hospital,” American Journal of the Medical Sciences 275 (1978): 271–82.
239. Gerald J. Jogerst and Stephen E. Dippe, “Antibiotic Use among Medical Specialties in a Community Hospital,” JAMA 245 (1981): 842–46.
240. John E. McGowan and Maxwell Finland, “Effects of Monitoring the Usage of Antibiotics: An Interhospital Comparison,” Southern Medical Journal 69 (1976): 193–95.
241. Calvin M. Kunin and Herman Y. Efron, “Audits of Antimicrobial Usage: Guidelines for Peer Review,” JAMA 237 (1977): 1001–2.
242. William A. Craig et al., “Hospital Use of Antimicrobial Drugs: Survey at 19 Hospitals and Results of Antimicrobial Control Program,” Annals of Internal Medicine 89 part 2 (1978): 793–95.
243. Rose A. Recco, “Antibiotic Control in a Municipal Hospital,” JAMA 241 (1979): 2283–86.
244. Robert Edelman, “Introduction,” Annals of Internal Medicine 89 part 2 (1978): 741.
245. Robert Bud, The Uses of Life: A History of Biotechnology(New York: Cambridge University Press, 1993), 174.
246. Susan Wright, Molecular Politics: Developing American and British Regulatory Policy for Genetic Engineering(Chicago: University of Chicago Press, 1994).
247. Donald S. Fredrickson, The Recombinant DNA Controversy: Science, Politics, and the Public Interest, 1974–1981 (Washington, DC: ASM Press, 2001)
248. E. S. Anderson, “The Problem and Implications of Chloramphenicol Resistance in the Typhoid Bacillus,” Journal of Hygiene74 (1975): 289–99.
249. L. S. Tomkins, J. J. Plorde, and S. Falkow, “Molecular Analysis of RFactors from Multiresistant Nosocomial Isolates,” Journal of Infectious Diseases141 (1980): 625–36.
250. Wendell H. Hall, “The Abuse and Misuse of Antibiotics,” Minnesota Monthly 35 (1952): 629.
251. George R. Fisher, “The Use and Abuse of Antibiotics,” Journal of the Iowa State Medical Society 50 (1960): 245.
252. Louis Weinstein, “Antibiotics: I. General Considerations,” in Louis Goodman and Alfred Gilman, eds., The Pharmacological Basis of Therapeutics, 3rd ed. (New York: Macmillan, 1965), 1187.
253. Charlotte Muller, “The Overmedicated Society: Forces in the Marketplace for Medical Care,” Science176 (1972): 488–92.
254. ars L. Gustafsson and Katarina Wild, “Marketing of Obsolete Antibiotics in Central America,” Lancet1 (1981): 31–33.
255. Thomas F. O’Brien, Ralph L. Kent, and Antone A. Medeiros, “Computer Generated Plots of Results of Antimicrobial-Susceptibility Tests,” JAMA210 (1969): 84–92.
256. Thomas F. O’Brien et al., “International Comparison of Prevalence of Resistance to Antibiotics,” JAMA239 (1978): 1518–23.
257. Calvin M. Kunin, “The Responsibility of the Infectious Disease Community,” Journal of Infectious Diseases151 (1985): 388–98.
258. Tim Beardsley, “NIH Retreat from Controversy,” Nature319 (1986): 611.
259. Frank M. Snowden, “Emerging and Reemerging Diseases: A Historical Perspective,” Immunological Reviews 225 (2008): 9–26.
260. Nancy Tomes, “The Making of a Germ Panic, Then and Now,” American Journal of Public Health90 (2000): 191–98.
261. Stuart B. Levy, The Antibiotic Paradox: How Miracle Drugs are Destroying the Miracle (New York: Plenum, 1992).
262. Mitchell L. Cohen, “Epidemiology of Drug Resistance: Implications for a Post-Antimicrobial Era,” Science 257 (1992): 1050–55.
263. Harold C. Neu, “The Crisis in Antibiotic Resistance,” Science 257 (1992): 1064–72.
264. Sharon Begley, “The End of Antibiotics?” Newsweek (Mar. 7, 1994): 63.
265. Richard S. Saver, “In Tepid Defense of Population Health: Physicians and Antibiotic Resistance,” American Journal of Law and Medicine 34 (2008): 431–91.
266. Selman A. Waksman, The Antibiotic Era: A History of Antibiotics and of Their Role in the Conquest of Infectious Diseases and in Other Fields of Human Endeavor (Tokyo: Waksman Foundation of Japan, 1975).
267. John Harley Warner, The Therapeutic Perspective: Medical Practice, Knowledge, and Identity in America, 1820–1885(Cambridge, MA: Harvard University Press, 1986).
268. Charles S. Bryan and Scott H. Podolsky, “Dr. Holmes at 200—The Spirit of Skepticism,” NEJM361 (2009): 846–47.
269. James Whorton, “ ‘Antibiotic Abandon’: The Resurgence of Therapeutic Rationalism,” in John Parascandola, ed., The History of Antibiotics: A Symposium(Madison, WI: American Institute of the History of Pharmacy, 1980), 125–36.
270. Daniel J. Shapiro, Lauri A. Hicks, Andrew T. Pavia, and Adam L. Hersh, “Antibiotic Prescribing for Adults in Ambulatory Care in the USA, 2007–09,” Journal of Antimicrobial Chemotherapy69 (2014): 234–40.
271. Michael L. Barnett and Jeffrey A. Linder, “Antibiotic Prescribing to Adults with Sore Throat in the United States, 1997–2010,” JAMA Internal Medicine174 (2014): 138–40.
272. Jeanne Daly, Evidence-Based Medicine and the Search for a Science of Clinical Care(Berkeley: University of California Press, 2005), 89.
273. Ian M. Gould and Jos W. M. van der Meer, eds., Antibiotic Policies: Theory and Practice(New York: Kluwer Academic /Plenum Publishers, 2005), 545–66.
274. Gaia Lusini et al., “Antibiotic Prescribing in Paediatric Populations: A Comparison between Viareggio, Italy and Funen, Denmark,” European Journal of Public Health19 (2009): 434–38.
275. S. Mölstad et al., “Sustained Reduction of Antibiotic Use and Low Bacterial Resistance: 10-Year Follow-up of the Swedish Strama Programme,” Lancet Infectious Diseases8 (2008): 125–32.
276. K. A. Holloway, V. Ivanovska, A. K. Wagner, C. Vialle-Valentin, and D. Ross-Degnan, “Have We Improved Use of Medicines in Developing and Transitional Countries and Do We Know How To? Two Decades of Evidence,” Tropical Medicine and International Health18 (2013): 656–64.
277. Salmaan Keshavjee and Paul E. Farmer, “Tuberculosis, Drug Resistance, and the History of Modern Medicine,” NEJM367 (2012): 931–36.
278. Jean Dubos, The White Plague: Tuberculosis, Man, and Society(Boston: Little, Brown, 1952).
279. Paul Farmer, “Social Scientists and the New Tuberculosis,” Social Science and Medicine44 (1997): 347–58.
280. Paul Farmer, Jaime Bayona, and Mercedes Becerra, “Multidrug-resistant Tuberculosis and the Need for Biosocial Perspectives,” International Journal of Lung Disease5 (2001): 885–86.
281. C. A. Hart and S. Kariuki, “Antimicrobial Resistance in Developing Countries,” British Medical Journal317 (1998): 647–50.
282. Robert Edelman, “Socioeconomic and Behavioral Factors Leading to Acquired Bacterial Resistance to Antibiotics in Developing Countries,” Emerging Infectious Diseases5 (1999): 18–27.
283. Margaret B. Planta, “The Role of Poverty in Antimicrobial Resistance,” Journal of the American Board of Family Medicine20 (2007): 533–39.
284. Henry Welch, “Opening Remarks,” Antibiotics Annual (1956-1957): 1–2.
285. Iruke N. Okeke et al., “Antimicrobial Resistance in Developing Countries. Part II: Strategies for Containment,” Lancet Infectious Diseases5 (2005): 568–80.
286. Calvin M. Kunin, “The Responsibility of the Infectious Disease Community for the Optimal Use of Antimicrobial Agents,” Journal of Infectious Diseases 151 (1985): 389.